

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Francisco Sanchez-Madrid Confirmation No.: 1583  
SERIAL NUMBER: 10/770,639 EXAMINER : SKELDING, ZACHARY S  
FILING DATE: February 2, 2004 ART UNIT : 1644  
FOR: IMMUNE REGULATION BASED ON THE TARGETING OF EARLY ACTIVATION  
MOLECULES

**Mail Stop AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Information Disclosure Statement is being filed after the mailing date of a first Office Action based on the merits but before the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by the fee set forth in 37 CFR § 1.17(p). As such, payment in the amount of \$180.00 as set forth in 37 CFR § 1.17(p) for submission of an Information Disclosure Statement under 37 CFR § 1.97(c) is filed herewith.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed PTO Form SB/08(a) with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or

APPLICANT: **Francisco Sanchez-Madrid**  
U.S.S.N.: **10/770,639**

that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **27331-501CIP2A**.

Respectfully submitted,

/Sheridan K. Snedden/  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
Sheridan K. Snedden, Reg. No. 55,998  
Attorneys for Applicants  
MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer no.: 30623**

Dated: February 17, 2010

4839715v.1